Value of quantitative and qualitative analyses of serum and urine cell-free DNA as diagnostic tools for bladder cancer: a meta-analysis

Cao, Zhangjun; Peng, Longfei; He, Ke; Wang, Xin; Lu, Youlu; Zhang, Ying; Bi, Liangkuan

doi:10.1080/14737140.2019.1626723

Cited by 5 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ucfDNAs also gain attention due to their close contact with lesions of urinary disease and are therefore considered potential urine biomarkers for BC. 26,27 Recent clinical research found that ucfDNA can monitor the recurrence and progression of NMIBC. Xu et al 28 enrolled 103 patients with NMIBC (pTa-pT1) and measured the IQGAP3/BMP4 expression ratios in ucfDNA by real-time quantitative polymerase chain reaction (RT-qPCR).…”

Section: Cell-free Dna and Circulating Tumour Dnamentioning

confidence: 99%

“…Currently, plasma cfDNA is widely explored for its potential in tumour detection. ucfDNAs also gain attention due to their close contact with lesions of urinary disease and are therefore considered potential urine biomarkers for BC 26,27 . Recent clinical research found that ucfDNA can monitor the recurrence and progression of NMIBC.…”

Section: The Presence Of Genomic Dna In Urine Of Bc Patientsmentioning

confidence: 99%

“…Cytokeratin, one of the intermediate filament proteins of the epithelial cytoskeleton, is another commonly used biomarker for BC detection. 27 After epithelial cell death, cytokeratin is released into urine, and its concentration can be detected to predict the absence or presence of BC. 84 It has been demonstrated that cytokeratin 8, 18, 19 and 20 are significantly associated with the progression BC.…”

Section: Urine Protein Markers In Bcmentioning

confidence: 99%

See 2 more Smart Citations

Recent development of urinary biomarkers for bladder cancer diagnosis and monitoring

Zeng

Wang

et al. 2023

Clinical and Translational Dis

View full text Add to dashboard Cite

Urine‐based liquid biopsy has emerged as a non‐invasive and effective tool for early screening and diagnosis of bladder cancer. This review provides a comprehensive overview of the current urine‐based biomarkers and methods for the detection and monitoring of bladder cancer. We focus on biomarkers including tumour DNAs, proteins, microbiome, tumour RNAs, long non‐coding RNAs, transfer RNA‐derived fragments, messenger RNAs, microRNAs, circular RNAs, exosomes and extrachromosomal circular DNA.

show abstract

Section: Cell-free Dna and Circulating Tumour Dnamentioning

confidence: 99%

Section: The Presence Of Genomic Dna In Urine Of Bc Patientsmentioning

confidence: 99%

Section: Urine Protein Markers In Bcmentioning

confidence: 99%

See 1 more Smart Citation

Recent development of urinary biomarkers for bladder cancer diagnosis and monitoring

Zeng

Wang

et al. 2023

Clinical and Translational Dis

View full text Add to dashboard Cite

show abstract

“…Moreover, the sensitivity of cystoscopy for the diagnosis of bladder cancer in situ is not high enough, and about 10% of the lesions are missed. Besides, cystoscopy may also cause complications such as urinary tract infections and bleeding (5,6). Another commonly used method is urine exfoliated cytology test.…”

Section: Introductionmentioning

confidence: 99%

“…Another commonly used method is urine exfoliated cytology test. The technique has high sensitivity in G3 and high-grade tumors (84%), but low sensitivity in G1and low-tumors (16%) (5,7). Therefore, the search for novel biomarkers with high sensitivity and specificity for early detection of bladder cancer is urgently needed (8).…”

Section: Introductionmentioning

confidence: 99%

A novel cell-free single-molecule unique primer extension resequencing (cf-SUPER) technology for bladder cancer non-invasive detection in urine

Zhao¹,

Pan²,

Wang³

et al. 2020

Transl Androl Urol

View full text Add to dashboard Cite

Background: The clinical diagnostic method for bladder cancer is cystoscopy, an invasive, expensive and inconvenient clinical test. Using urinary cell-free DNA (cfDNA) to develop non-invasive test for bladder cancer was a promising liquid biopsy.Methods: To improve the using rate of cfDNA template and decrease the PCR bias for liquid biopsy using urinary cfDNA, we developed a cell-free single-molecule unique primer extension resequencing (cf-SUPER) technology which was done for 29 matched urinary cfDNA and tumor DNA samples of bladder cancer patients to evaluate consistency of mutation profiles. Then, a 22 high mutational frequence genes was selected to form an uriprier panel, which was analyzed in 100 patients (47 bladder cancer cases and 53 controls) using cf-SUPER technology. This performance of the technology was evaluated using bioinformatic tools and clinical samples. Results:The study showed that cf-SUPER technology can accurately detect mutations with allele fractions even low as 0.01% and the DNA input as low as 1 ng. The consistency of mutation profiles and clinical pathological diagnose between 29 matched urinary cfDNA and tumor DNA samples was respectively 82.76% and 89.66% by using cf-SUPER technology. Using cf-SUPER technology, the sensitivity and specificity were 98%, 94% respectively for uriprier panel in non-invasive test. Conclusions:The preliminary work shows that cf-SUPER technology will be a promising method for liquid biopsy. Focusing urinary cfDNA, the non-invasive diagnose and monitoring of bladder cancer can come true by using cf-SUPER technology.

show abstract

Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic Disease

Garofoli,

Maiorano,

Bruno

et al. 2024

European Urology Oncology

View full text Add to dashboard Cite

Value of quantitative and qualitative analyses of serum and urine cell-free DNA as diagnostic tools for bladder cancer: a meta-analysis

Cited by 5 publications

References 30 publications

Recent development of urinary biomarkers for bladder cancer diagnosis and monitoring

Recent development of urinary biomarkers for bladder cancer diagnosis and monitoring

A novel cell-free single-molecule unique primer extension resequencing (cf-SUPER) technology for bladder cancer non-invasive detection in urine

Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic Disease

Contact Info

Product

Resources

About